Just curious, but if Inovio has a piece of this action by way of its licensing to Oncosec, why not own them and benefit from the potential of the cancer and the DNA and other products in their pipeline? No disrespect to ONCS , but it seems like a lesser risk, greater reward scenario. Not a wet blanket comment, appreciate thoughtful responses.
If Inovio had all the money they needed they would being doing it all themselves. The only problem they don't have unlimited cash so they must pick their battles they want to fight and at what cost. It's all about how many studies Inovio can afford to fund and what they are best at addressing from their perspective. There are a lot of diseases that can possibly be effected by electroporation. It just boils down to which do you have the money to fund and which do they want to let others fund such as ONCS.
So yes you can play both if ONCS has positive results than INO will benefit as well. It's like Microsoft licensing to both HP, DELL and IBM. Microsoft did very well with this way of thinking and I believe their stock did too for those original investors if I recall correctly.